EyeBio is a biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. Here are details of EyeBio‘s latest funding round :
🚀 Launch
2021
🏭 Industry
Biotechnology
🧠Management
David Guyer, Tony Adamis (Co-founders)
💸 Funding & Investors
| INVESTMENT (Novembre 2023) | $65 million (Series A) |
| INVESTORS (Novembre 2023) | Bain Capital Life Sciences, Omega Funds and Vertex Ventures HC and from existing investors SV Health Investors, Jeito Capital, Samsara Biocapital and MRL Ventures Fund. |
🎯 Funding purpose
Accelerate its clinical development program and further build out its innovative retina pipeline.
🌐 Country HQ
UK (London)